2025-10-23T10:00:36-05:00 2024-12-31 251622758 MAHER DUESSEL CPA'S 503 MARTINDALE STREET SUITE 600 PITTSBURGH PA 15212 990 2024-01-01 460902111 RTOG FOUNDATION INC RTOG 2157170834 50 S 16TH STREET 2800 PHILADELPHIA PA 19102 QUYNH-THU LE CHAIRMAN 2157170834 2025-10-23 1 0 AMY LEWIS P01360302 4124715500 2024 2025-03-06 01:10:19Z QUYNH-THU LE 50 S 16TH STREET 2800 PHILADELPHIA PA 19102 14000061 0 X WWW.RTOG.ORG X 2012 PA TO ORGANIZE & PROVIDE FUNDING FOR MULTI-CENTER CLINICAL RESEARCH ACTIVITIES IN ONCOLOGY. 14 14 0 14 0 0 4287692 4176134 8144072 9362425 181070 420007 27000 41495 12639834 14000061 0 0 0 0 0 0 0 0 0 11664696 12705224 11664696 12705224 975138 1294837 16896589 20327245 7983192 10250384 8913397 10076861 X THE MISSION OF RTOG FOUNDATION, INC. (RTOGF) IS TO:(1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS, (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH, (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION, (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOGF'S MEMBERSHIP IN NRG ONCOLOGY, (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOGF'S RESEARCH MISSION, (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOGF IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES, AND (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOGF RESEARCH ENTERPRISE. 0 0 11805923 9403920 RTOG'S PRIMARY PROGRAM CONSTITUTES THE FOLLOWING: (1) IMPROVE THE SURVIVAL OUTCOME AND QUALITY OF LIFE OF ADULTS WITH CANCER THROUGH THE CONDUCT OF HIGH-QUALITY CLINICAL TRIALS, (2) EVALUATE NEW FORMS OF RADIOTHERAPY DELIVERY AND TEST NEW SYSTEMIC AND TARGETED THERAPIES IN CONJUNCTION WITH RADIOTHERAPY IN THE CONTEXT OF CLINICAL RESEARCH, (3) PARTICIPATE AS ONE OF THREE MEMBER ORGANIZATIONS IN THE ACTIVITIES OF NRG ONCOLOGY FOUNDATION, (4) DEVELOP AND CONDUCT PRACTICE-CHANGING CLINICAL TRIALS FOR THE NCI NATIONAL CLINICAL TRIAL NETWORK (NCTN) THROUGH RTOG'S MEMBERSHIP IN NRG ONCOLOGY, (5) DEVELOP AND CONDUCT INDUSTRY-SUPPORTED CLINICAL TRIALS THAT ARE IMPORTANT TO RTOG'S RESEARCH MISSION, (6) PROVIDE FUNDING FOR BASIC, CLINICAL, AND TRANSLATIONAL INVESTIGATORS TO COLLABORATE WITH RTOG IN THE DEVELOPMENT OF BOTH BIOLOGIC AND BIOPHYSICAL TARGETED THERAPIES, AND (7) SUPPORT YOUNG INVESTIGATORS FROM MANY DISCIPLINES WITHIN THE RTOG RESEARCH ENTERPRISE. 11805923 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 12 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 14 14 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 PA X JULIE KARDELL 2155743150 50 S 16TH STREET 2800 PHILADELPHIA PA 19102 X DOW WILSON DIRECTOR 1.00 X 0 0 0 GRAHAM BURNETTE ESQ DIRECTOR 1.00 X 0 0 0 JEFF MICHALSKI MD MBA TREASURER 1.00 X X 0 0 0 JIM DIGNAM PHD DIRECTOR 1.00 X 0 0 0 KRISTIN HIGGINS MD DIRECTOR 1.00 X 0 0 0 LISA KACHNIC MD DIRECTOR 1.00 X 0 0 0 MITCHELL MACHTAY MD PRESIDENT & CEO 5.00 X X 0 0 0 QUYNH LE MD CHAIR 5.00 X X 0 0 0 SETH ROSENTHAL MD DIRECTOR 1.00 X 0 0 0 STUART WONG MD SECRETARY 1.00 X X 0 0 0 SUE YOM MD DIRECTOR 1.00 X 0 0 0 WALTER J CURRAN JR MD DIRECTOR 1.00 X 0 0 0 MARK MISHRA MD DIRECTOR 1.00 X 0 0 0 EDWIN POSADAS MD DIRECTOR 1.00 X 0 0 0 0 0 0 0 0 0 0 UNIVERSITY OF CALIFORNIA -UCSF 2340 SUTTER ST ROOM S341 SAN FRANCISCO CA 94115 BIOSPECIMEN BANKING 848667 RXCROSSROADS BY MCKESSON P O BOX 846025 DALLAS TX 75284 DRUG DISTRIBUTION 466200 NSABP FOUNDATION INC 2 1200 ALLEGHENY SQUARE E PITTSBURGH PA 15212 ACCOUNTING AND CONSULTING 273004 ALLIANCE FOR CLINICAL TRIALS IN ONCOLOGY 311 SOUTH WACKER DRIVE - SUITE 2650 CHICAGO IL 60606 TRIAL SPECIMEN STUDIES 186000 THE UNIVERSITY OF TEXAS MD ANDERSON CANC 1515 HOLCOMBE BLVD HOUSTON TX 77030 RESEARCH STUDIES 179079 10 4157465 18669 4176134 INDUSTRY REVENUE 541700 9362425 9362425 9362425 420007 420007 MISCELLANEOUS 900099 41495 41495 41495 14000061 9403920 0 420007 X 12324 12324 460573 2800 457773 1427702 1350274 77428 2683 2683 4989 4989 23508 23508 SUB-AWARD RESEARCH PROJ 8506060 8198577 307483 SITE EXPENSES 2242249 2242249 MISCELLANEOUS 13396 387 13009 POSTAGE & SHIPPING 11740 11636 104 12705224 11805923 899301 0 4019617 8232069 6689964 3702103 5182333 5097505 15281 2390687 1004675 889600 16896589 20327245 3820636 2342111 4162556 7908273 7983192 10250384 X 8913397 10076861 8913397 10076861 16896589 20327245 1294837 -131373 0 X X 0 1 X 1 1 1 X 2684323 5887228 4276831 4287692 4176134 21312208 2684323 5887228 4276831 4287692 4176134 21312208 21312208 2 1 5 181070 420007 601085 402 27000 41495 68897 21982190 30625327 0.96950 0.99070 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: REIMBURSEMENTS - 2020 AMOUNT: $ 402. SDMC INCOME - 2023 AMOUNT: $ 27,000. 2024 AMOUNT: $ 41,495. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 13868688 -131373 -131373 14000061 0 14000061 12705224 0 12705224 0 12705224 FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. THE RETURN WILL THEN BE REVIEWED BY THE SECRETARY-TREASURER AND APPROVED. THE RETURN WILL THEN BE MADE AVAILABLE FOR ALL DIRECTORS PRIOR TO ITS FILING. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY APPLIES TO BOARD MEMBERS, OFFICERS, COMMITTEE MEMBERS, STAFF, VOLUNTEERS, CLINICAL INVESTIGATORS, AND ALL OTHERS REPRESENTING OR ACTING ON BEHALF OT RTOGF. IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF THE FINANCIAL INTEREST. THE DISCLOSURE IS REVIEWED BY THE RTOGF ADMINISTRATOR WITH GUIDANCE FROM RTOGF LEGAL COUNSEL. ANY INDENTIFIED FINANCIAL CONFLICT OF INTEREST (FCOI) WILL BE REVIEWED WITH THE AFFECTED INVESTIGATOR AND, IF APPLICABLE, REPORTED TO NIH WITHIN 60 DAYS OF DISCOVERY AND ACTIONS TO MANAGE, REDUCE, OR ELIMINATE THE FCOI WILL BE TAKEN BT THE ADMINISTRATOR OF THE RESEARCH ACTIVITY INVOLVED AND INCLUDED IN THE REPORT TO NATIONAL INSTITUTES OF HEALTH (NIH). MANAGEMENT OF AN IDENTIFIED FCOI WILL INCLUDE THE DEVELOPMENT AND IMPLEMENTATION OF A MANAGEMENT PLAN AND, IF NECESSARY, A RETROSPECTIVE REVIEW AND MITIGATION REPORT. FORM 990, PART VI, SECTION C, LINE 19 THE GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL SERVICES: PROGRAM SERVICE EXPENSES 1,350,274. MANAGEMENT AND GENERAL EXPENSES 77,428. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,427,702. FORM 990, PART XII, LINE 2C: THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR. NRG ONCOLOGY FOUNDATION INC 1600 JFK BOULEVARD SUITE 1020 PHILADELPHIA PA 19103 900912747 ONCOLOGY RESEARCH SUPPORT PA 501(C)(3) LINE 7 N/A 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 NRG ONCOLOGY FOUNDATION INC C 4157465 ACTUAL GRANTS